ReviewPharmaceutics2023
Recent Advancements in the Development of Nanocarriers for Mucosal Drug Delivery Systems to Control Oral Absorption.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 44 citations in OpenAlex.
- Engineering Oral Nanoparticles: Navigating Biological Barriers in the Gastrointestinal Tract.Pharmaceutical research · 2026Review
- Liposomal Nanocarriers in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Formulation Design, Targeting Strategies, and Therapeutic Outcomes.Current issues in molecular biology · 2026Review
- Bergapten as a Multifunctional Phytochemical in Cancer Therapy: Mechanistic Insights, Pharmacokinetics, and Possible Nanotechnology-Enabled Formulation Strategies.Pharmaceutics · 2026Review
- Advancing Treatment of Degenerative Eye Diseases at the Nanoscale.Smart medicine · 2026Review
- [Oral mucosal administration].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026Article
- Hybrid Mucointeractive Delivery Systems-Alternative Approaches to Mucosal Delivery.Molecules (Basel, Switzerland) · 2026Review
- In Vitro Evaluation of Novel Nano-Sized Colloidal Assemblies Incorporating Hydrophobic Tobramycin Ion Pairs: Enhanced Cellular Uptake with Preserved Antimicrobial Activity Toward Oral Drug Delivery.Molecules (Basel, Switzerland) · 2026Article
- Barrier-Oriented Design of Next-Generation Polymeric Nanocarriers for Targeted Drug Delivery.Molecules (Basel, Switzerland) · 2026Review
- Tableting of nanoparticle-based formulations for oral delivery: Enhancing biopharmaceutical performance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Novel liquid-based approaches for transmucosal drug delivery.Acta pharmaceutica Sinica. B · 2026Review
- Advanced oral drug delivery systems: Current challenges and emerging technologies.Acta pharmaceutica Sinica. B · 2026Review
- Nanobiotic-Enhanced Probiotics for Targeted Gut Delivery: Mechanisms, Therapeutic Applications, and Translational Challenges.International journal of nanomedicine · 2026Review
- Targeted phytotherapy: essential oils, multi-target cancer action & nanodelivery.Frontiers in oncology · 2026Review
- Bridging bioactive metabolites ofFrontiers in pharmacology · 2026Review
- Nanomedicine for Oral Delivery: Strategies to Overcome the Biological Barriers.Small methods · 2026Review
- Pharmacological Management of Cancer Pain: Advances in Treatment Strategies and Drug Delivery Systems.Pharmaceutics · 2025Review
- Exploring bioadhesion: insight on innovative strategies to investigate bioadhesive scaffolds.International journal of pharmaceutics: X · 2025Review
- Gel Delivery Systems in Dental Medicine: From Controlled Release to Regenerative Applications.Gels (Basel, Switzerland) · 2025Review
- Ginseng-Derived Carbon Quantum Dots Enhance Systemic Exposure of Bioactive Ginsenosides and Amplify Energy Metabolism in Mice.Pharmaceutics · 2025Article
- Targeting the Oral Mucosa: Emerging Drug Delivery Platforms and the Therapeutic Potential of Glycosaminoglycans.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral administration of active pharmaceutical ingredients is desirable because it is easy, safe, painless, and can be performed by patients, resulting in good medication adherence. The mucus layer in the gastrointestinal (GI) tract generally acts as a barrier to protect the epithelial membrane from foreign substances; however, in the absorption process after oral administration, it can also disturb effective drug absorption by trapping it in the biological sieve structured by mucin, a major component of mucus, and eliminating it by mucus turnover. Recently, functional nanocarriers (NCs) have attracted much attention due to their immense potential and effectiveness in the field of oral drug delivery. Among them, NCs with mucopenetrating and mucoadhesive properties are promising dosage options for controlling drug absorption from the GI tracts. Mucopenetrating and mucoadhesive NCs can rapidly deliver encapsulated drugs to the absorption site and/or prolong the residence time of NCs close to the absorption membrane, providing better medications than conventional approaches. The surface characteristics of NCs are important factors that determine their functionality, owing to the formation of various kinds of interactions between the particle surface and mucosal components. Thus, a deeper understanding of surface modifications on the biopharmaceutical characteristics of NCs is necessary to develop the appropriate mucosal drug delivery systems (mDDS) for the treatment of target diseases. This review summarizes the basic information and functions of the mucosal layer, highlights the recent progress in designing functional NCs for mDDS, and discusses their performance in the GI tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.